[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537263":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":40,"responsibleParty":58,"collaborators":25,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":25,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":25,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":25,"overallStatus":42,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"bivalirudin group","EXPERIMENTAL","If the creatinine clearance rate \\> 30ml\u002Fmin, the initial dose of bivalirudin is 0.04mg\u002Fkg\u002Fh. If the creatinine clearance rate\\\u003C30ml\u002Fmin or the patients who have received renal replacement therapy (CRRT), the initial dose of bivalirudin is 0.02mg\u002Fkg\u002Fh, and the dose is adjusted according to APPT to maintain APTT at 40-60s. After bivalirudin started, APTT was checked every 4 hours. If APTT was in the target range twice in a row, it was re-examined every 12 hours.",[13],"Drug: bivalirudin",{"label":15,"type":6,"description":16,"interventionNames":17},"unfractionated heparin group","The initial dose of heparin was 8-12U\u002Fkg\u002Fh, and the dosage of heparin was adjusted according to the value of APTT. APTT was maintained at 40-60s, and APTT was reexamined every 4 hours.",[18],"Drug: unfractionated heparin",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","bivalirudin","bivalirudin as an anticoagulant",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"unfractionated heparin","unfractionated heparin as an anticoagulant",[15],[31],{"name":32,"affiliation":5,"role":33},"Liangshan Wang, MD","STUDY_CHAIR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Xiaotong Hou, MD","CONTACT","010-64456631","xt.hou@ccmu.edu.cn",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Beijing","Beijing Municipality","100029","China","CN",{"type":49,"coordinates":50},"Point",[51,52],116.39723,39.9075,{"lat":52,"lon":51},[55],{"name":32,"role":37,"phone":56,"phoneExt":25,"email":57},"86-13811363372","wangliangshanbam@sina.com",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Xiaotong Hou","Clinical professor","100537263","use-of-bivalirudin-for-anticoagulation-in-patients-with-extracorporeal-membrane-oxygenation-100537263",false,"NCT06275555","Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation","Efficacy and Safety of Bivalirudin Versus Heparin in Anticoagulant Therapy of ECMO: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Accept VA-ECMO or VV-ECMO\n3. the ECMO team believes that systemic anticoagulation is necessary and that APTT should be maintained at 40-60s.\n4. sign the informed consent form\n\nExclusion Criteria:\n\n1. previous history of allergy to heparin or bivalirudin\n2. previous diagnosis of heparin-induced thrombocytopenia.\n3. the pre-random ECMO assistance time is more than 48 hours.\n4. pregnant female\n5. have participated in this study before.\n6. the researchers believe that there are other factors that are not suitable to participate in this study.","ALL","18 Years",{"count":72,"type":73},154,"ESTIMATED","INTERVENTIONAL",[76],"NA","The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.",[79],"Extracorporeal Membrane Oxygenation Complication","2026-04-02",{"date":82,"type":83},"2026-04-06","ACTUAL",{"date":85,"type":83},"2024-06-03",{"date":87,"type":73},"2027-03-01",{"name":60,"class":6},1]